Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VIR 
Vir Biotechnology Inc (VIR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/26/2025: VIR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $17.22
1 Year Target Price $17.22
| 2 | Strong Buy |
| 5 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -74.18% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 893.18M USD | Price to earnings Ratio - | 1Y Target Price 17.22 |
Price to earnings Ratio - | 1Y Target Price 17.22 | ||
Volume (30-day avg) 9 | Beta 1.35 | 52 Weeks Range 4.16 - 14.45 | Updated Date 11/29/2025 |
52 Weeks Range 4.16 - 14.45 | Updated Date 11/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.62 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date 2025-10-30 | When - | Estimate -0.8407 | Actual -1.17 |
Profitability
Profit Margin - | Operating Margin (TTM) -72267.91% |
Management Effectiveness
Return on Assets (TTM) -25.97% | Return on Equity (TTM) -49.06% |
Valuation
Trailing PE - | Forward PE 4.36 | Enterprise Value 482670954 | Price to Sales(TTM) 52.98 |
Enterprise Value 482670954 | Price to Sales(TTM) 52.98 | ||
Enterprise Value to Revenue 34.58 | Enterprise Value to EBITDA 0.9 | Shares Outstanding 139125032 | Shares Floating 96851891 |
Shares Outstanding 139125032 | Shares Floating 96851891 | ||
Percent Insiders 10.44 | Percent Institutions 78.27 |
Upturn AI SWOT
Vir Biotechnology Inc
Company Overview
History and Background
Vir Biotechnology, Inc. was founded in 2016 with the mission to combat infectious diseases. It has focused on developing treatments for diseases like hepatitis B, influenza A, and COVID-19, leveraging its advanced technologies to identify and develop promising therapeutic candidates.
Core Business Areas
- Infectious Disease Therapeutics: Focuses on developing treatments and preventative measures for a variety of infectious diseases, including viral diseases.
- Antibody Discovery: Utilizes proprietary antibody discovery platforms to identify and develop monoclonal antibodies for therapeutic use.
Leadership and Structure
The company has a leadership team of scientists and business professionals. The organizational structure is typical of a biotechnology firm, with research, development, and commercial operations.
Top Products and Market Share
Key Offerings
- Sotrovimab (Xevudy): A monoclonal antibody treatment for COVID-19, developed in partnership with GSK. The drug has faced restrictions due to Omicron variants, impacting its market share. Competitors include Paxlovid (PFE) and Lagevrio (MRK).
- VIR-2218 (Tofersen): An investigational siRNA therapeutic in phase 2 trials for chronic hepatitis B virus (HBV) infection. Key competitors are developing novel therapeutics in the HBV space. No market share or revenue available at this stage.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high R&D spending, long development timelines, and significant regulatory oversight. It is driven by innovation and unmet medical needs.
Positioning
Vir Biotechnology is positioned as a research-driven company focused on developing innovative therapeutics for infectious diseases. Its competitive advantage lies in its proprietary antibody discovery platforms and strategic partnerships.
Total Addressable Market (TAM)
The TAM for infectious disease therapeutics is substantial and growing, driven by emerging pathogens and the increasing prevalence of chronic infections. Vir is targeting specific segments within this large TAM, such as COVID-19 and HBV.
Upturn SWOT Analysis
Strengths
- Proprietary antibody discovery platform
- Strategic partnerships with major pharmaceutical companies (e.g., GSK)
- Focus on high-need infectious diseases
- Experienced leadership team
Weaknesses
- Reliance on partnerships for commercialization
- Dependence on success of clinical trials
- Fluctuating revenue based on COVID-19 treatment demand
- High R&D expenditure
Opportunities
- Expansion of pipeline through new drug discovery
- Acquisition of complementary technologies or companies
- Geographic expansion into emerging markets
- Development of preventative vaccines or therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Emergence of new variants or drug resistance
Competitors and Market Share
Key Competitors
- PFE
- MRK
- GILD
- ABBV
Competitive Landscape
Vir's advantages include its innovative antibody discovery platform and focus on specific infectious diseases. Its disadvantages include its smaller size and limited commercial infrastructure compared to larger pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been influenced by the demand for Sotrovimab during the COVID-19 pandemic. Growth in other areas is contingent on clinical trial outcomes and regulatory approvals.
Future Projections: Future growth is dependent on the successful development and commercialization of pipeline products. Analyst estimates vary based on clinical trial progress and market conditions.
Recent Initiatives: Recent initiatives include advancing clinical trials for VIR-2218 and exploring new partnerships for drug development and commercialization.
Summary
Vir Biotechnology is a promising company focused on infectious disease therapeutics, with a strong antibody discovery platform. Its past success was influenced by COVID-19 treatments, but future growth depends on its pipeline and partnerships. Clinical trial outcomes and competition from larger firms pose challenges.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (Publicly Available)
- Industry News
Disclaimers:
The analysis provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vir Biotechnology Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2019-10-11 | CEO & Director Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 408 | Website https://www.vir.bio |
Full time employees 408 | Website https://www.vir.bio | ||
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.